Winnie Byanyima, from UNAIDS: ‘Lenacapavir is more effective than condoms or PrEP in prevention’
The executive director of the organization says gender inequality is one of the most important drivers of new infections, ...
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational ...
News Medical on MSN1d
Affordability and supply remain critical to the success of long-lasting HIV drugAffordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
In this randomized controlled trial, among adolescent girls and young women, it was found that twice-yearly lenacapavir ...
The U.S Food and Drug Administration ( FDA) has confirmed the availability of lenacapavir, a two-yearly injectable HIV/ADS treatment as early as the summer 2025, a decision made by FDA after the ...
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
GILD's recent upbeat data on lenacapavir underscore the investigational drug???s potential to prevent HIV in the targeted ...
The treatment combines MSD’s islatravir, an experimental nucleoside reverse transcriptase inhibitor, with Gilead’s ...
New data from the PURPOSE 2 trial continue to show the efficacy of lenacapavir in HIV prevention in individuals who have sex ...
3d
Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback